|Bid||1.480 x 0|
|Ask||1.485 x 0|
|Day's range||1.470 - 1.500|
|52-week range||1.190 - 3.405|
|PE ratio (TTM)||N/A|
|Earnings date||23 May 2018 - 28 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.06|
NEW YORK and MELBOURNE, Australia, April 18, 2018-- Mesoblast Limited today provided an update on the Phase 3 and Phase 2 b clinical trials of the Company's proprietary allogeneic mesenchymal precursor ...
NEW YORK and MELBOURNE, Australia, March 28, 2018-- Mesoblast Limited today announced that enrollment has completed in the Phase 3 trial evaluating a single intra-discal injection of its proprietary allogeneic ...
MELBOURNE, Australia and NEW YORK, March 06, 2018-- Mesoblast Limited today announced that it has entered into a US $75 million non-dilutive, four-year credit facility with Hercules Capital, Inc., a leading ...
MELBOURNE, Australia and NEW YORK, Feb. 27, 2018-- Mesoblast Limited today provided the market with an update on its operational highlights and consolidated financial results for the six months ended December ...
NEW YORK and MELBOURNE, Australia, Feb. 26, 2018-- Mesoblast Limited today announced it will report financial results for the first half year ended December 31, 2017 in a webcast beginning at 4:30 pm EST ...
NEW YORK and MELBOURNE, Australia, Feb. 21, 2018-- Mesoblast Limited today announced that the Phase 3 trial of its allogeneic mesenchymal stem cell product candidate MSC-100-IV in children with steroid ...
The early hope that stem cell therapy would make the paralysed walk, the blind see and cure diabetes have given way to a long list of failures, highlighted by early stem cell champion Geron Corp abandoning the field in 2011. Both have overcome major hurdles to manufacturing stem cell treatments on a large scale that are off-the-shelf products derived from healthy donor bone marrow and do not face immune system rejection issues. Australia's Mesoblast, with a market value of about $US500 million ($A652.86 million), is attempting to alter advanced heart failure, a leading cause of hospitalisations and deaths and an enormous cost burden.
NEW YORK & MELBOURNE, Australia--(BUSINESSWIRE)-- Mesoblast Limited has been named by Frost & Sullivan as the 2017 Global Technology Leader in the Cell Therapy Industry. Mesoblast is a biopharma company ...
Caterpillar, Avon Products, JA Solar Holdings, Mesoblast and 21Vianet Group highlighted as Zacks Bull and Bear of the Day
At Zacks, we suggest that investors pay close attention to our proven stock-picking system, which stresses the importance of earnings estimate revisions in finding winning stocks. But we also understand that lower-priced stocks often make attractive investments, and we will always cover stocks that are making newsworthy moves, big or small.